A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

Completed · Phase 3 · Has a placebo group

Conditions studied: Transient Insomnia

In brief

The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.

Key facts

Study ID

NCT00674752

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

377

Starts

2006-03-01

Expected to finish

2006-08-01

Last updated by the study team

2021-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged >/= 18 years who reported occasional sleeplessness in the month prior to screening
• Females of child-bearing potential using medically-acceptable method of birth control >/= 1 month prior to screening

You may not qualify if…

• Current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition)
• Currently taking or expected to take any of the following during the trial: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbituates, and phencyclidine

Where it is running

• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.